open access

Vol 13, No 1 (2018)
Review Papers
Published online: 2018-03-22
Get Citation

The role of galectin 3 as a diagnostic and prognostic marker in cardiology

Przemysław Święcki, Małgorzata Knapp, Anna Lisowska
DOI: 10.5603/FC.2018.0005
·
Folia Cardiologica 2018;13(1):29-34.

open access

Vol 13, No 1 (2018)
Review Papers
Published online: 2018-03-22

Abstract

Galectin 3 (Gal-3) is a protein belonging to family lectins. Gal-3 is produced as a response to inflammatory mediators
by several types of cells directly associated with atherosclerosis such as macrophages and endothelial cells. Galectin
3 represents a link between inflammation and fibrosis. Gal-3 is a biomarker associated with inflammation and cardiac
fibrosis in patients with heart failure. Association of galectin 3 with cardiovascular risk factors suggest that it can be
a promising marker of subclinical and symptomatic atherosclerosis. Previous research suggest that Gal-3 may be a useful
diagnostics marker and prognostic factor in ischaemic heart disease and heart failure.

Abstract

Galectin 3 (Gal-3) is a protein belonging to family lectins. Gal-3 is produced as a response to inflammatory mediators
by several types of cells directly associated with atherosclerosis such as macrophages and endothelial cells. Galectin
3 represents a link between inflammation and fibrosis. Gal-3 is a biomarker associated with inflammation and cardiac
fibrosis in patients with heart failure. Association of galectin 3 with cardiovascular risk factors suggest that it can be
a promising marker of subclinical and symptomatic atherosclerosis. Previous research suggest that Gal-3 may be a useful
diagnostics marker and prognostic factor in ischaemic heart disease and heart failure.

Get Citation

Keywords

galectin 3, atherosclerosis, cardiovascular risk factors, ischaemic heart disease, heart failure

About this article
Title

The role of galectin 3 as a diagnostic and prognostic marker in cardiology

Journal

Folia Cardiologica

Issue

Vol 13, No 1 (2018)

Pages

29-34

Published online

2018-03-22

DOI

10.5603/FC.2018.0005

Bibliographic record

Folia Cardiologica 2018;13(1):29-34.

Keywords

galectin 3
atherosclerosis
cardiovascular risk factors
ischaemic heart disease
heart failure

Authors

Przemysław Święcki
Małgorzata Knapp
Anna Lisowska

References (40)
  1. Bazaeva EV, Myasnikov RP, Metelskaya VA, et al. [Diagnostic Value of Biochemical Markers in Patients With Chronic Heart Failure With Reduced, Borderline and Preserved Left Ventricular Ejection Fraction]. Kardiologiia. 2017; 57(3): 39–45.
  2. Aksan G, Gedikli Ö, Keskin K, et al. Is galectin-3 a biomarker, a player-or both-in the presence of coronary atherosclerosis? J Investig Med. 2016; 64(3): 764–770.
  3. Sharma UC, Mosleh W, Chaudhari MR, et al. Myocardial and Serum Galectin-3 Expression Dynamics Marks Post-Myocardial Infarction Cardiac Remodelling. Heart Lung Circ. 2017; 26(7): 736–745.
  4. Dumic J, Dabelic S, Flögel M. Galectin-3: an open-ended story. Biochim Biophys Acta. 2006; 1760(4): 616–635.
  5. Argüeso P, Panjwani N. Focus on molecules: galectin-3. Exp Eye Res. 2011; 92(1): 2–3.
  6. de Boer RA, Voors AA, Muntendam P, et al. Galectin-3: a novel mediator of heart failure development and progression. Eur J Heart Fail. 2009; 11(9): 811–817.
  7. Shah RV, Chen-Tournoux AA, Picard MH, et al. Galectin-3, cardiac structure and function, and long-term mortality in patients with acutely decompensated heart failure. Eur J Heart Fail. 2010; 12(8): 826–832.
  8. Ozturk D, Celik O, Satilmis S, et al. Association between serum galectin-3 levels and coronary atherosclerosis and plaque burden/structure in patients with type 2 diabetes mellitus. Coron Artery Dis. 2015; 26(5): 396–401.
  9. He XW, Li WL, Li C, et al. Serum levels of galectin-1, galectin-3, and galectin-9 are associated with large artery atherosclerotic stroke. Sci Rep. 2017; 7: 40994.
  10. Imran TF, Shin HJ, Mathenge N, et al. Meta-Analysis of the Usefulness of Plasma Galectin-3 to Predict the Risk of Mortality in Patients With Heart Failure and in the General Population. Am J Cardiol. 2017; 119(1): 57–64.
  11. Winter MP, Wiesbauer F, Alimohammadi A, et al. Soluble galectin-3 is associated with premature myocardial infarction. Eur J Clin Invest. 2016; 46(5): 386–391.
  12. Jin Qh, Lou Yf, Li Tl, et al. Serum galectin-3: a risk factor for vascular complications in type 2 diabetes mellitus. Chin Med J (Engl). 2013; 126(11): 2109–2115.
  13. Medvedeva EA, Berezin II, Shchukin YV, et al. [Galectin-3, Markers of Oxidative Stress and Renal Dysfunction in Patients With Chronic Heart Failure]. Kardiologiia. 2017; 57(3): 46–50.
  14. McCullough PA, Olobatoke A, Vanhecke TE. Galectin-3: a novel blood test for the evaluation and management of patients with heart failure. Rev Cardiovasc Med. 2011; 12(4): 200–210.
  15. Medvedeva EA, Berezin II, Surkova EA, et al. Galectin-3 in patients with chronic heart failure: association with oxidative stress, inflammation, renal dysfunction and prognosis. Minerva Cardioangiol. 2016; 64(6): 595–602.
  16. Chen K, Jiang RJ, Wang CQ, et al. Predictive value of plasma galectin-3 in patients with chronic heart failure. Eur Rev Med Pharmacol Sci. 2013; 17(8): 1005–1011.
  17. Stoltze Gaborit F, Bosselmann H, Kistorp C, et al. Galectin 3: association to neurohumoral activity, echocardiographic parameters and renal function in outpatients with heart failure. BMC Cardiovasc Disord. 2016; 16: 117.
  18. Lisowska A, Knapp M, Tycińska A, et al. Predictive value of Galectin-3 for the occurrence of coronary artery disease and prognosis after myocardial infarction and its association with carotid IMT values in these patients: A mid-term prospective cohort study. Atherosclerosis. 2016; 246: 309–317.
  19. Amin HZ, Amin LZ, Wijaya IP. Galectin-3: a novel biomarker for the prognosis of heart failure. Clujul Med. 2017; 90(2): 129–132.
  20. Zhang R, Zhang Y, An T, et al. Prognostic value of sST2 and galectin-3 for death relative to renal function in patients hospitalized for heart failure. Biomark Med. 2015; 9(5): 433–441.
  21. Stolen CM, Adourian A, Meyer TE, et al. Plasma galectin-3 and heart failure outcomes in MADIT-CRT (multicenter automatic defibrillator implantation trial with cardiac resynchronization therapy). J Card Fail. 2014; 20(11): 793–799.
  22. Gandhi PU, Motiwala SR, Belcher AM, et al. Galectin-3 and mineralocorticoid receptor antagonist use in patients with chronic heart failure due to left ventricular systolic dysfunction. Am Heart J. 2015; 169(3): 404–411.e3.
  23. Sanders-van Wijk S, Masson S, Milani V, et al. TIME-CHF Investigators and the GISSI-HF Investigators. Interaction of Galectin-3 Concentrations with the Treatment Effects of β-Blockers and RAS Blockade in Patients with Systolic Heart Failure: A Derivation-Validation Study from TIME-CHF and GISSI-HF. Clin Chem. 2016; 62(4): 605–616.
  24. Gullestad L, Ueland T, Kjekshus J, et al. CORONA Study Group. Galectin-3 predicts response to statin therapy in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). Eur Heart J. 2012; 33(18): 2290–2296.
  25. Anand IS, Rector TS, Kuskowski M, et al. Baseline and serial measurements of galectin-3 in patients with heart failure: relationship to prognosis and effect of treatment with valsartan in the Val-HeFT. Eur J Heart Fail. 2013; 15(5): 511–518.
  26. Calvier L, Legchenko E, Grimm L, et al. Galectin-3 and aldosterone as potential tandem biomarkers in pulmonary arterial hypertension. Heart. 2016; 102(5): 390–396.
  27. Filipe MD, Meijers WC, Rogier van der Velde A, et al. Galectin-3 and heart failure: prognosis, prediction & clinical utility. Clin Chim Acta. 2015; 443: 48–56.
  28. Yancy CW, Jessup M, Bozkurt B, et al. WRITING COMMITTEE MEMBERS, American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013; 128(16): e240–e327.
  29. Lala RI, Lungeanu D, Darabantiu D, et al. Galectin-3 as a marker for clinical prognosis and cardiac remodeling in acute heart failure. Herz. 2017 [Epub ahead of print].
  30. Sudharshan S, Novak E, Hock K, et al. Use of Biomarkers to Predict Readmission for Congestive Heart Failure. Am J Cardiol. 2017; 119(3): 445–451.
  31. Falcone C, Lucibello S, Mazzucchelli I, et al. Galectin-3 plasma levels and coronary artery disease: a new possible biomarker of acute coronary syndrome. Int J Immunopathol Pharmacol. 2011; 24(4): 905–913.
  32. Milner TD, Viner AC, MacKinnon AC, et al. Temporal expression of galectin-3 following myocardial infarction. Acta Cardiol. 2014; 69(6): 595–602.
  33. Kruk M, Menon V, Kądziela J, et al. Impact of percutaneous coronary intervention on biomarker levels in patients in the subacute phase following myocardial infarction: the Occluded Artery Trial (OAT) biomarker ancillary study. BMC Cardiovasc Disord. 2013; 13: 91.
  34. Bivona G, Bellia C, Lo Sasso B, et al. Short-term Changes in Gal 3 Circulating Levels After Acute Myocardial Infarction. Arch Med Res. 2016; 47(7): 521–525.
  35. Jansen H, Koenig W, Jaensch A, et al. Prognostic Utility of Galectin-3 for Recurrent Cardiovascular Events During Long-term Follow-up in Patients with Stable Coronary Heart Disease: Results of the KAROLA Study. Clin Chem. 2016; 62(10): 1372–1379.
  36. A VA, Zaslavskaya EL, Soboleva AV, et al. [Galectin-3 in Patients With Paroxysmal and Persistent Atrial Fibrillation and Metabolic Syndrome]. Kardiologiia. 2016; 56(6): 41–45.
  37. Kocyigit D, Gurses KM, Yalcin MU, et al. Serum galectin-3 level as a marker of thrombogenicity in atrial fibrillation. J Clin Lab Anal. 2017; 31(6).
  38. Clementy N, Benhenda N, Piver E, et al. Serum Galectin-3 Levels Predict Recurrences after Ablation of Atrial Fibrillation. Sci Rep. 2016; 6: 34357.
  39. Gawor M, Śpiewak M, Janas J, et al. The usefulness of sST2 and galectin-3 as novel biomarkers for better risk stratification in hypertrophic cardiomyopathy. Kardiol Pol. 2017; 75(10): 997–1004.
  40. Oz F, Onur I, Elitok A, et al. Galectin-3 correlates with arrhythmogenic right ventricular cardiomyopathy and predicts the risk of ventricular -arrhythmias in patients with implantable defibrillators. Acta Cardiol. 2017; 72(4): 453–459.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

 

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl